Skip to content

Svennilson Peter

Follow

13F filer, CIK 1606074, SAN FRANCISCO, CA

Svennilson Peter reported $321,765,000 across 4 holdings for the quarter ended 2019-09-30, in a 13F-HR filed 2019-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000903514-19-000008

Period
2019-09-30
Reported value
$322M
Holdings
4
Top 10 weight
100%
New
0
Sold out
0

Stakes and trades reported after 2019-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
    Accepted , ingested
  • TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CONSTELLATION PHARMACEUTICALadded+1,331,763$8.6M
NGM BIOPHARMACEUTICALS INCadded+472,816$6.55M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q3 2019

Share positions as resolved from 13F-HR 0000903514-19-000008, largest first. % of portfolio is the value over $321,765,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: 15,694,091 shares; 2019Q3: 16,166,907 shares 16,166,907$224M69.59%+472,816
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 4,677,938 shares; 2019Q1: 4,677,939 shares; 2019Q2: 4,677,939 shares; 2019Q3: 6,009,702 shares 6,009,702$38.8M12.07%+1,331,763
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,540,850 shares; 2019Q1: 3,540,850 shares; 2019Q2: 3,540,850 shares; 2019Q3: 3,540,850 shares 3,540,850$32.2M10.01%0Timeline
GRITSTONE BIO INCGRITSTONE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,102,934 shares; 2019Q1: 3,102,934 shares; 2019Q2: 3,102,934 shares; 2019Q3: 3,102,934 shares 3,102,934$26.8M8.33%0

How Q3 2019 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000903514-19-000008 base2019-11-14acceptance time not in the bulk data set